Multiple Sclerosis Drugs

Multiple Sclerosis Drugs Comprehensive Study by Type (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary-Progressive MS (PPMS), Secondary-Progressive MS (SPMS)), Route of Administration (Injectable, Oral), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2030

Multiple Sclerosis Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Type
  • Clinically Isolated Syndrome (CIS)
  • Relapsing-Remitting MS (RRMS)
  • Primary-Progressive MS (PPMS)
  • Secondary-Progressive MS (SPMS)
By Route of Administration
  • Injectable
  • Oral

By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing instances of Multiple Sclerosis
      • 3.2.2. Increasing Awareness about health problems among people
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Multiple Sclerosis Medication
    • 3.4. Market Trends
      • 3.4.1. Increased Spending on Health
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiple Sclerosis Drugs, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Multiple Sclerosis Drugs (Value)
      • 5.2.1. Global Multiple Sclerosis Drugs by: Type (Value)
        • 5.2.1.1. Clinically Isolated Syndrome (CIS)
        • 5.2.1.2. Relapsing-Remitting MS (RRMS)
        • 5.2.1.3. Primary-Progressive MS (PPMS)
        • 5.2.1.4. Secondary-Progressive MS (SPMS)
      • 5.2.2. Global Multiple Sclerosis Drugs by: Route of Administration (Value)
        • 5.2.2.1. Injectable
        • 5.2.2.2. Oral
      • 5.2.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Multiple Sclerosis Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Multiple Sclerosis Drugs (Volume)
      • 5.3.1. Global Multiple Sclerosis Drugs by: Type (Volume)
        • 5.3.1.1. Clinically Isolated Syndrome (CIS)
        • 5.3.1.2. Relapsing-Remitting MS (RRMS)
        • 5.3.1.3. Primary-Progressive MS (PPMS)
        • 5.3.1.4. Secondary-Progressive MS (SPMS)
      • 5.3.2. Global Multiple Sclerosis Drugs by: Route of Administration (Volume)
        • 5.3.2.1. Injectable
        • 5.3.2.2. Oral
      • 5.3.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Multiple Sclerosis Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Multiple Sclerosis Drugs (Price)
      • 5.4.1. Global Multiple Sclerosis Drugs by: Type (Price)
  • 6. Multiple Sclerosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genzyme Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mallinckrodt (Unite States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Multiple Sclerosis Drugs Sale, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Multiple Sclerosis Drugs (Value)
      • 7.2.1. Global Multiple Sclerosis Drugs by: Type (Value)
        • 7.2.1.1. Clinically Isolated Syndrome (CIS)
        • 7.2.1.2. Relapsing-Remitting MS (RRMS)
        • 7.2.1.3. Primary-Progressive MS (PPMS)
        • 7.2.1.4. Secondary-Progressive MS (SPMS)
      • 7.2.2. Global Multiple Sclerosis Drugs by: Route of Administration (Value)
        • 7.2.2.1. Injectable
        • 7.2.2.2. Oral
      • 7.2.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Multiple Sclerosis Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Multiple Sclerosis Drugs (Volume)
      • 7.3.1. Global Multiple Sclerosis Drugs by: Type (Volume)
        • 7.3.1.1. Clinically Isolated Syndrome (CIS)
        • 7.3.1.2. Relapsing-Remitting MS (RRMS)
        • 7.3.1.3. Primary-Progressive MS (PPMS)
        • 7.3.1.4. Secondary-Progressive MS (SPMS)
      • 7.3.2. Global Multiple Sclerosis Drugs by: Route of Administration (Volume)
        • 7.3.2.1. Injectable
        • 7.3.2.2. Oral
      • 7.3.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Multiple Sclerosis Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Multiple Sclerosis Drugs (Price)
      • 7.4.1. Global Multiple Sclerosis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiple Sclerosis Drugs: by Type(USD Million)
  • Table 2. Multiple Sclerosis Drugs Clinically Isolated Syndrome (CIS) , by Region USD Million (2018-2023)
  • Table 3. Multiple Sclerosis Drugs Relapsing-Remitting MS (RRMS) , by Region USD Million (2018-2023)
  • Table 4. Multiple Sclerosis Drugs Primary-Progressive MS (PPMS) , by Region USD Million (2018-2023)
  • Table 5. Multiple Sclerosis Drugs Secondary-Progressive MS (SPMS) , by Region USD Million (2018-2023)
  • Table 6. Multiple Sclerosis Drugs: by Route of Administration(USD Million)
  • Table 7. Multiple Sclerosis Drugs Injectable , by Region USD Million (2018-2023)
  • Table 8. Multiple Sclerosis Drugs Oral , by Region USD Million (2018-2023)
  • Table 9. Multiple Sclerosis Drugs: by Distribution Channel(USD Million)
  • Table 10. Multiple Sclerosis Drugs Online , by Region USD Million (2018-2023)
  • Table 11. Multiple Sclerosis Drugs Offline , by Region USD Million (2018-2023)
  • Table 12. South America Multiple Sclerosis Drugs, by Country USD Million (2018-2023)
  • Table 13. South America Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 14. South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 15. South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 16. Brazil Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 17. Brazil Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 18. Brazil Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 19. Argentina Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 20. Argentina Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 21. Argentina Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. Rest of South America Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 24. Rest of South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Asia Pacific Multiple Sclerosis Drugs, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 28. Asia Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 29. China Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 30. China Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 31. China Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 32. Japan Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 33. Japan Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 34. Japan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 35. India Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 36. India Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 37. India Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 38. South Korea Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 39. South Korea Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 40. South Korea Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 41. Taiwan Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 42. Taiwan Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 43. Taiwan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 44. Australia Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 45. Australia Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 46. Australia Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. Europe Multiple Sclerosis Drugs, by Country USD Million (2018-2023)
  • Table 51. Europe Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 52. Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 53. Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 54. Germany Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 55. Germany Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 56. Germany Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 57. France Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 58. France Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 59. France Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 60. Italy Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 61. Italy Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 62. Italy Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. United Kingdom Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 65. United Kingdom Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Netherlands Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 67. Netherlands Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 68. Netherlands Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 69. Rest of Europe Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 71. Rest of Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. MEA Multiple Sclerosis Drugs, by Country USD Million (2018-2023)
  • Table 73. MEA Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 74. MEA Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 75. MEA Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 76. Middle East Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 77. Middle East Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 78. Middle East Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 79. Africa Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 80. Africa Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 81. Africa Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 82. North America Multiple Sclerosis Drugs, by Country USD Million (2018-2023)
  • Table 83. North America Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 84. North America Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 85. North America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 86. United States Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 87. United States Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 88. United States Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 89. Canada Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 90. Canada Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 91. Canada Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. Mexico Multiple Sclerosis Drugs, by Type USD Million (2018-2023)
  • Table 93. Mexico Multiple Sclerosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 94. Mexico Multiple Sclerosis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 95. Multiple Sclerosis Drugs Sales: by Type(K Tons)
  • Table 96. Multiple Sclerosis Drugs Sales Clinically Isolated Syndrome (CIS) , by Region K Tons (2018-2023)
  • Table 97. Multiple Sclerosis Drugs Sales Relapsing-Remitting MS (RRMS) , by Region K Tons (2018-2023)
  • Table 98. Multiple Sclerosis Drugs Sales Primary-Progressive MS (PPMS) , by Region K Tons (2018-2023)
  • Table 99. Multiple Sclerosis Drugs Sales Secondary-Progressive MS (SPMS) , by Region K Tons (2018-2023)
  • Table 100. Multiple Sclerosis Drugs Sales: by Route of Administration(K Tons)
  • Table 101. Multiple Sclerosis Drugs Sales Injectable , by Region K Tons (2018-2023)
  • Table 102. Multiple Sclerosis Drugs Sales Oral , by Region K Tons (2018-2023)
  • Table 103. Multiple Sclerosis Drugs Sales: by Distribution Channel(K Tons)
  • Table 104. Multiple Sclerosis Drugs Sales Online , by Region K Tons (2018-2023)
  • Table 105. Multiple Sclerosis Drugs Sales Offline , by Region K Tons (2018-2023)
  • Table 106. South America Multiple Sclerosis Drugs Sales, by Country K Tons (2018-2023)
  • Table 107. South America Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 108. South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 109. South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 110. Brazil Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 111. Brazil Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 112. Brazil Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 113. Argentina Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 114. Argentina Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 115. Argentina Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 116. Rest of South America Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 117. Rest of South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 118. Rest of South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 119. Asia Pacific Multiple Sclerosis Drugs Sales, by Country K Tons (2018-2023)
  • Table 120. Asia Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 121. Asia Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 122. Asia Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 123. China Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 124. China Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 125. China Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 126. Japan Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 127. Japan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 128. Japan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 129. India Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 130. India Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 131. India Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 132. South Korea Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 133. South Korea Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 134. South Korea Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 135. Taiwan Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 136. Taiwan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 137. Taiwan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 138. Australia Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 139. Australia Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 140. Australia Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 141. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 142. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 143. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 144. Europe Multiple Sclerosis Drugs Sales, by Country K Tons (2018-2023)
  • Table 145. Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 146. Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 147. Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 148. Germany Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 149. Germany Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 150. Germany Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 151. France Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 152. France Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 153. France Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 154. Italy Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 155. Italy Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 156. Italy Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 157. United Kingdom Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 158. United Kingdom Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 159. United Kingdom Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 160. Netherlands Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 161. Netherlands Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 162. Netherlands Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 163. Rest of Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 164. Rest of Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 165. Rest of Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 166. MEA Multiple Sclerosis Drugs Sales, by Country K Tons (2018-2023)
  • Table 167. MEA Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 168. MEA Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 169. MEA Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 170. Middle East Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 171. Middle East Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 172. Middle East Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 173. Africa Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 174. Africa Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 175. Africa Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 176. North America Multiple Sclerosis Drugs Sales, by Country K Tons (2018-2023)
  • Table 177. North America Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 178. North America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 179. North America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 180. United States Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 181. United States Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 182. United States Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 183. Canada Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 184. Canada Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 185. Canada Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 186. Mexico Multiple Sclerosis Drugs Sales, by Type K Tons (2018-2023)
  • Table 187. Mexico Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 188. Mexico Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 189. Multiple Sclerosis Drugs: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Multiple Sclerosis Drugs: by Type(USD Million)
  • Table 199. Multiple Sclerosis Drugs Clinically Isolated Syndrome (CIS) , by Region USD Million (2025-2030)
  • Table 200. Multiple Sclerosis Drugs Relapsing-Remitting MS (RRMS) , by Region USD Million (2025-2030)
  • Table 201. Multiple Sclerosis Drugs Primary-Progressive MS (PPMS) , by Region USD Million (2025-2030)
  • Table 202. Multiple Sclerosis Drugs Secondary-Progressive MS (SPMS) , by Region USD Million (2025-2030)
  • Table 203. Multiple Sclerosis Drugs: by Route of Administration(USD Million)
  • Table 204. Multiple Sclerosis Drugs Injectable , by Region USD Million (2025-2030)
  • Table 205. Multiple Sclerosis Drugs Oral , by Region USD Million (2025-2030)
  • Table 206. Multiple Sclerosis Drugs: by Distribution Channel(USD Million)
  • Table 207. Multiple Sclerosis Drugs Online , by Region USD Million (2025-2030)
  • Table 208. Multiple Sclerosis Drugs Offline , by Region USD Million (2025-2030)
  • Table 209. South America Multiple Sclerosis Drugs, by Country USD Million (2025-2030)
  • Table 210. South America Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 211. South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 212. South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 213. Brazil Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 214. Brazil Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 215. Brazil Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 216. Argentina Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 217. Argentina Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 218. Argentina Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 219. Rest of South America Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 220. Rest of South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 221. Rest of South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 222. Asia Pacific Multiple Sclerosis Drugs, by Country USD Million (2025-2030)
  • Table 223. Asia Pacific Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 224. Asia Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 225. Asia Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 226. China Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 227. China Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 228. China Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 229. Japan Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 230. Japan Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 231. Japan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 232. India Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 233. India Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 234. India Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 235. South Korea Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 236. South Korea Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 237. South Korea Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 238. Taiwan Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 239. Taiwan Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 240. Taiwan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 241. Australia Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 242. Australia Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 243. Australia Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 247. Europe Multiple Sclerosis Drugs, by Country USD Million (2025-2030)
  • Table 248. Europe Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 249. Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 250. Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 251. Germany Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 252. Germany Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 253. Germany Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 254. France Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 255. France Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 256. France Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 257. Italy Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 258. Italy Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 259. Italy Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 260. United Kingdom Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 261. United Kingdom Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 262. United Kingdom Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 263. Netherlands Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 264. Netherlands Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 265. Netherlands Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 266. Rest of Europe Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 267. Rest of Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 268. Rest of Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 269. MEA Multiple Sclerosis Drugs, by Country USD Million (2025-2030)
  • Table 270. MEA Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 271. MEA Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 272. MEA Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 273. Middle East Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 274. Middle East Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 275. Middle East Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 276. Africa Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 277. Africa Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 278. Africa Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 279. North America Multiple Sclerosis Drugs, by Country USD Million (2025-2030)
  • Table 280. North America Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 281. North America Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 282. North America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 283. United States Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 284. United States Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 285. United States Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 286. Canada Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 287. Canada Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 288. Canada Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 289. Mexico Multiple Sclerosis Drugs, by Type USD Million (2025-2030)
  • Table 290. Mexico Multiple Sclerosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 291. Mexico Multiple Sclerosis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 292. Multiple Sclerosis Drugs Sales: by Type(K Tons)
  • Table 293. Multiple Sclerosis Drugs Sales Clinically Isolated Syndrome (CIS) , by Region K Tons (2025-2030)
  • Table 294. Multiple Sclerosis Drugs Sales Relapsing-Remitting MS (RRMS) , by Region K Tons (2025-2030)
  • Table 295. Multiple Sclerosis Drugs Sales Primary-Progressive MS (PPMS) , by Region K Tons (2025-2030)
  • Table 296. Multiple Sclerosis Drugs Sales Secondary-Progressive MS (SPMS) , by Region K Tons (2025-2030)
  • Table 297. Multiple Sclerosis Drugs Sales: by Route of Administration(K Tons)
  • Table 298. Multiple Sclerosis Drugs Sales Injectable , by Region K Tons (2025-2030)
  • Table 299. Multiple Sclerosis Drugs Sales Oral , by Region K Tons (2025-2030)
  • Table 300. Multiple Sclerosis Drugs Sales: by Distribution Channel(K Tons)
  • Table 301. Multiple Sclerosis Drugs Sales Online , by Region K Tons (2025-2030)
  • Table 302. Multiple Sclerosis Drugs Sales Offline , by Region K Tons (2025-2030)
  • Table 303. South America Multiple Sclerosis Drugs Sales, by Country K Tons (2025-2030)
  • Table 304. South America Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 305. South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 306. South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 307. Brazil Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 308. Brazil Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 309. Brazil Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 310. Argentina Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 311. Argentina Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 312. Argentina Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 313. Rest of South America Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 314. Rest of South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 315. Rest of South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 316. Asia Pacific Multiple Sclerosis Drugs Sales, by Country K Tons (2025-2030)
  • Table 317. Asia Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 318. Asia Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 319. Asia Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 320. China Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 321. China Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 322. China Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 323. Japan Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 324. Japan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 325. Japan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 326. India Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 327. India Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 328. India Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 329. South Korea Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 330. South Korea Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 331. South Korea Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 332. Taiwan Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 333. Taiwan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 334. Taiwan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 335. Australia Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 336. Australia Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 337. Australia Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 338. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 339. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 340. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 341. Europe Multiple Sclerosis Drugs Sales, by Country K Tons (2025-2030)
  • Table 342. Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 343. Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 344. Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 345. Germany Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 346. Germany Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 347. Germany Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 348. France Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 349. France Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 350. France Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 351. Italy Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 352. Italy Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 353. Italy Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 354. United Kingdom Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 355. United Kingdom Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 356. United Kingdom Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 357. Netherlands Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 358. Netherlands Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 359. Netherlands Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 360. Rest of Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 361. Rest of Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 362. Rest of Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 363. MEA Multiple Sclerosis Drugs Sales, by Country K Tons (2025-2030)
  • Table 364. MEA Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 365. MEA Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 366. MEA Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 367. Middle East Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 368. Middle East Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 369. Middle East Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 370. Africa Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 371. Africa Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 372. Africa Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 373. North America Multiple Sclerosis Drugs Sales, by Country K Tons (2025-2030)
  • Table 374. North America Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 375. North America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 376. North America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 377. United States Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 378. United States Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 379. United States Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 380. Canada Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 381. Canada Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 382. Canada Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 383. Mexico Multiple Sclerosis Drugs Sales, by Type K Tons (2025-2030)
  • Table 384. Mexico Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 385. Mexico Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 386. Multiple Sclerosis Drugs: by Type(USD/Units)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiple Sclerosis Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Multiple Sclerosis Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Multiple Sclerosis Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 8. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 9. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 10. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 11. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 12. Global Multiple Sclerosis Drugs: by Type K Tons (2018-2023)
  • Figure 13. Global Multiple Sclerosis Drugs: by Route of Administration K Tons (2018-2023)
  • Figure 14. Global Multiple Sclerosis Drugs: by Distribution Channel K Tons (2018-2023)
  • Figure 15. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 16. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 17. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 18. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 19. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 20. Global Multiple Sclerosis Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Global Multiple Sclerosis Drugs share by Players 2023 (%)
  • Figure 22. Global Multiple Sclerosis Drugs share by Players (Top 3) 2023(%)
  • Figure 23. Global Multiple Sclerosis Drugs share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 27. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genzyme Corporation (United States) Revenue: by Geography 2023
  • Figure 29. Teva Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 35. Mallinckrodt (Unite States) Revenue, Net Income and Gross profit
  • Figure 36. Mallinckrodt (Unite States) Revenue: by Geography 2023
  • Figure 37. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc (United States) Revenue: by Geography 2023
  • Figure 39. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Global Multiple Sclerosis Drugs: by Type USD Million (2025-2030)
  • Figure 42. Global Multiple Sclerosis Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 43. Global Multiple Sclerosis Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 44. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 45. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 46. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 47. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 48. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 49. Global Multiple Sclerosis Drugs: by Type K Tons (2025-2030)
  • Figure 50. Global Multiple Sclerosis Drugs: by Route of Administration K Tons (2025-2030)
  • Figure 51. Global Multiple Sclerosis Drugs: by Distribution Channel K Tons (2025-2030)
  • Figure 52. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 53. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 54. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 55. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 56. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 57. Global Multiple Sclerosis Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bristol Myers Squibb (United States)
  • Genzyme Corporation (United States)
  • Teva Pharmaceuticals (United States)
  • Roche Holding AG (Switzerland)
  • Merck KGaA (Germany)
  • Mallinckrodt (Unite States)
  • Pfizer Inc (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
Additional players considered in the study are as follows:
Par Pharmaceuticals (United States) , Cipla (India)
Select User Access Type

Key Highlights of Report


Apr 2024 208 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Multiple Sclerosis Drugs Quantitative research analysis
Multiple Sclerosis Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Multiple Sclerosis Drugs Report?

Have a Query? Click Here

Other Related Reports

Dog Care Comprehensive Study by Type (Dog Food, Treats & Chews, Toys & Training, Apparel & Accessories, Grooming & Healthcare, Shelter & Accessories, Other), Application (Young Dogs, Old Dogs), Distr...
$ 3450
Human DNA Vaccines Comprehensive Study by Type (Human DNA vaccines, Animal DNA vaccines), Application (Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung canc...
$ 3750
Thioctic Acid Comprehensive Study by Type (R-lipoic Acid, S-lipoic Acid), Application (Diabetes, Nerve Pain, Weight Loss, Skin Care, Others), Distribution Channel (Online (E-Commerce Stores), Offline...
$ 3650
Histidine Comprehensive Study by Type (Tablets, Capsules, Fluids, Others), Application (Food Industry, Pharmaceutical Industry, Biotechnology, R&D Laboratories, Medical Research Institutes, Others), ...
$ 3450
Animal Pharmaceutical Comprehensive Study by Type (Vaccines, Pharmaceuticals, Feed Additives, Diagnostics, Others), Application (Companion Animal, Poultry, Other), Disease (Orthopedic Diseases, Infec...
$ 3750
Creatine Kinase Comprehensive Study by Type (Kits & Reagents, Instruments), End-users (Hospitals, Clinics, Diagnostic Laboratories, Academic Research Institutes), Test Type (Colorimetric Assay Based ...
$ 3450